Regenxbio reports Q2 EPS ($1.38) vs. ($1.05) last year

Reports Q2 revenue $21.4M vs. $22.3M last year. “Our REGENXBIO (RGNX) team is accelerating multiple first or best-in-class gene therapies designed to improve the lives of patients and families facing serious diseases like Duchenne, Hunter syndrome, and retinal diseases. We continued our strong momentum in the second quarter of 2025, working with urgency to advance multiple pivotal programs, starting with the potential FDA approval of clemidsogene lanparvovec (RGX-121) this November,” said Curran M. Simpson, President and Chief Executive Officer of REGENXBIO. “RGX-202 is progressing rapidly through pivotal study, and today’s announcement of our progress in diabetic retinopathy enables another late-stage program with the goal of preventing vision loss in chronic retinal disease that impacts millions of patients.”